Could a pill replace IV therapy for MDS? new study investigates

NCT ID NCT06091267

Ongoing Disease control Sponsor: Otsuka Beijing Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares an oral drug (ASTX727) to an intravenous (IV) drug (decitabine) in 72 Chinese adults with myelodysplastic syndromes (MDS), a bone marrow disorder. Participants will receive both treatments in a crossover design to see if the pill works as well as the infusion. The goal is to find a more convenient treatment option.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ASTX727 (decitabine and cedazuridine)
What this could lead to: If it works, this could offer a more convenient oral treatment option for myelodysplastic syndromes, potentially replacing the need for IV infusions.
What could go wrong: This is an early-phase study with only 72 participants, so results may not be conclusive. The oral drug might not be as effective or could have different side effects than the IV version.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

The First Affiliated Hospital,Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.